recombinant human pro collagen col3a1  (R&D Systems)

Journal: The Journals of Gerontology Series A: Biological Sciences and Medical Sciences

Article Title: Transcriptional Profiling of Muscle in Females With Distal Radius Fracture and Functional Sarcopenia

doi: 10.1093/gerona/glae002

Figure Lengend Snippet: Transcripts With Altered Gene Expression in the EXP Compared to NORM

Article Snippet: Recombinant human pro-collagen COL1A1 (R&D System, Minneapolis, MN, USA, 6220-CL) 75 μg/mL and recombinant human pro-collagen COL3A1 (R&D System, 7294-CL) 75 μg/mL were incubated with 5 μg/mL recombinant human BMP-1 (R&D, 1927-ZN) for 2 hours.

Techniques: Gene Expression

Journal: International Journal of Molecular Sciences

Article Title: Small-Molecule-Mediated Suppression of BMP Signaling by Selective Inhibition of BMP1-Dependent Chordin Cleavage

doi: 10.3390/ijms24054313

Figure Lengend Snippet: NPL1010 and NPL3008 rarely inhibit BMP1-dependent COL3A1 cleavage. ( A ) COL3A1 cleavage assay. rhCOL3A1 was incubated with rhBMP1. The effects of NPL1010 and NPL3008 on BMP1-dependent rhCOL3A1 cleavage were analyzed using SDS–PAGE and Oriole staining. Arrows indicate full-length rhCOL3A1 and cleaved rhCOL3A1. ( B ) Statistical analysis of BMP1-dependent cleavage of COL3A1. The levels of noncleaved and cleaved COL3A1 were measured by performing densitometry of the Oriole-stained gel, and the percentage of cleaved COL3A1 was calculated based on the fragments detected at each molecular weight and background. **: p < 0.01 (Dunnett’s test). The error bar indicates +s.d. with individual data shown ( n = 4).

Article Snippet: Recombinant human BMP1 (rhBMP1, 0.276 mg/mL, dissolved in 25 mM HEPES containing 400 mM ammonium sulfate, R&D Systems, Minneapolis, MN, USA, catalog no. 1927-ZN-010) and recombinant human COL3A1 (rhCOL3A1, 0.336 mg/mL, dissolved in 25 mM sodium acetate containing 1 M NaCl, R&D Systems, catalog no. 7294-CL-020) were divided into aliquots and stored at −80 °C.

Techniques: Cleavage Assay, Incubation, SDS Page, Staining, Molecular Weight

Journal: eLife

Article Title: Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking human LAIR-collagen interaction

doi: 10.7554/elife.62927

Figure Lengend Snippet: Figure 6. NC410 increases collagen degradation products that correlate with tumor regression. (A) Schematic representation of the humanized murine tumor model used. HT-29 tumor was injected subcutaneously in the presence of human peripheral blood mononuclear cells. Mice were treated with NC410 or control by intraperitoneal injection, Q4D 4 doses followed by Q7D until endpoint. Mice were bled prior to start of experiment and weekly for 4 weeks. (B) Tumor growth kinetics with NC410. Asterisks indicate statistical significance: *p<0.05, ****p<0.0001, two-way ANOVA with Sidak multiple comparisons. (C) Analysis of collagen degradation products in serum at baseline, at weeks 1, 2, 3 and 4. reC1M: neo-epitope of MMP-2,9,13- mediated degradation of type I collagen; C3M: type III collagen degradation by MMP; C4M: type IV collagen degradation by MMP; C6M: neo-epitope of MMP-2-mediated degradation of type VI collagen; PRO-C3: pro-peptide of type III collagen/ECM formation/fibroblast activity; PRO-C6: pro-peptide of type VI collagen; VICM: neo-epitope of MMP-2,8, trypsin-mediated degradation of citrullinated vimentin; C4G: type IV collagen degraded by Figure 6 continued on next page

Article Snippet: The anti-human Fc antibody capture sensors (ForteBio) were first loaded with LAIR-2-Fc followed by an association step where the loaded sensor was dipped into wells containing human, mouse or rat collagen I (human, R&D Systems; mouse, Ray Biotech; rat, Yo Protein) or collagen III (human, R&D Systems; rat, Yo Protein).

Techniques: Injection, Control, Activity Assay